Search PubMed⌕ Search

PubMed · 7656559

ORDMKV: a computer program fitting proportional odds model for multi-state Markov process.

Abstract

ORDMKV is a computer program designed to fit a multi-state discrete-time Markov model for k-stages disease processes having an ordinal structure. The model consists of k transient states representing the increasing severity of the disease process, and the final state can be optionally chosen to be an absorbing state in cases such as death. The ordinal structure of the stages of the disease is modelled by using ordinal response models. Each row of the one-step transition probability matrix is modelled using a proportional odds model based on the cumulative transition probabilities. By using these ordinal response models, the number of parameters used to model the disease process can be reduced significantly not only with respect to a general discrete-time model, but also compared with a parsimonuos continuous-time model. A restricted model can be fitted by assuming that the effect of the covariables in the cumulative probability has common regression coefficients in all stages of the disease process. This assumption, if it holds, reduces the number of regression coefficients associated with each covariate to only one. The regression coefficients of this model are estimated via the method of maximum likelihood, using a quasi-Newton optimization algorithm. When the last state is considered as an absorbing state, it is possible to compute survival curves from the transient states of the process. The program was written in standard FORTRAN 77 and is illustrated using a four-state model to determine factors influencing diabetic retinopathy in young subjects with insulin-dependent diabetes mellitus.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

W Guo, G Marshall. 1995. ORDMKV: a computer program fitting proportional odds model for multi-state Markov process.. https://doi.org/10.1016/0169-2607(95)01625-4

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Pancreatin therapy in patients with insulin-treated diabetes mellitus and exocrine pancreatic insufficiency according to low fecal elastase 1 concentrations. Results of a prospective multi-centre trial.

BACKGROUND: Recently, high prevalence of exocrine dysfunction in diabetic populations has been reported. Patients with fecal elastase 1 concentration (FEC) <100 microg/g have also been demonstrated to suffer from steatorrhea in about 60% of cases, indicating the need of pancreatic enzyme replacement therapy. Until now, there have only been a few reports on the use of enzyme replacement therapy in diabetic patients with exocrine pancreatic insufficiency. This investigation was designed to evaluate the impact of enzyme-replacement therapy on glucose metabolism and diabetes treatment in a prospective study of insulin-treated patients with diabetes mellitus. METHODS: A total of 546 patients with diabetes mellitus requiring insulin treatment were screened for exocrine dysfunction by FEC measurements. One hundred and fifteen patients (21.1%) had FEC <100 microg/g (normal >200 microg/g). Of these, 95 patients entered the study and 80 patients were randomized to receive either pancreatin (Creon) (39 patients) or placebo (41 patients) in a double-blind manner. Parameters of glucose metabolism, diabetes therapy and clinical symptoms were recorded in standardized protocols for 16 weeks. RESULTS: During the observation phase of 16 weeks, there were no significant differences between both groups concerning HbA(1c), fasting glucose levels, 2-h pp glucose levels, clinical parameters and safety parameters. A reduction in mild and moderate hypoglycemia was observed in the pancreatin group at the end of the study. CONCLUSIONS: Pancreatin therapy can be used safely in patients with diabetes mellitus and exocrine dysfunction. Parameters of glucose metabolism were not improved by enzyme replacement therapy.

Diabetes Mellitus, Type 1↗